文献速递外周动脉疾病

活动性癌症患者外周血管介入的多中心结局

Multicenter Outcomes of Peripheral Vascular Interventions in Patients with Active Cancer.
PubMed 文献 · J Vasc Surg · 2026-10-09

该多中心回顾性研究纳入3,072例外周动脉疾病行血管内介入的患者,活动性癌症发生率为2.2%(N=68)。癌症患者围术期远端栓塞和主要截肢率更高,4年内死亡或截肢复合结局显著更差(63% vs 35.1%,P<0.001),主要由死亡率升高驱动(52.2% vs 28.3%,P<0.001)。癌症与死亡或主要截肢复合结局独立相关(aHR=2.24 [1.61-3.10])。

要点

  • 活动性癌症患者PVI围术期远端栓塞和大截肢风险更高
  • 癌症患者4年死亡或截肢复合结局显著更差,主要由死亡率驱动
  • 癌症与死亡或主要截肢复合结局独立相关(aHR=2.24)

核心结论

  • 活动性癌症在接受PVI的患者中占比较小,但显著影响围术期肢体结局和长期生存。

研究设计与样本

  • 多中心回顾性研究,合并3家三级中心2019-2023年血管质量倡议(VQI)PVI数据,并通过病历回顾补充癌症信息。
  • 共纳入3,072例因PAD(包括跛行、慢性肢体威胁性缺血和急性肢体缺血)行血管内介入的成人患者。

主要发现

  • 活动性癌症发生率为2.2%(N=68),肺癌最常见(30.9%,N=21),53%(N=36)为晚期(3/4期)。
  • 癌症患者围术期远端栓塞率更高(4.4% vs 0.6%,P=0.012),围术期主要截肢率更高(4.4% vs 1.3%,P=0.046)。
  • Kaplan-Meier分析显示癌症患者4年内死亡或截肢复合结局显著更高(63% vs 35.1%,P<0.001)。
  • 回归分析显示癌症与死亡或主要截肢复合结局独立相关(aHR=2.24 [1.61-3.10])。

临床怎么用

  • 对活动性癌症患者行PVI时,应充分评估围术期肢体风险和长期生存预期。
  • 癌症患者PVI后需加强围术期肢体监测,警惕远端栓塞和主要截肢。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cancer is typically associated with venous thrombosis, but its impact on patients undergoing peripheral vascular interventions (PVI) for concomitant peripheral arterial disease (PAD) remains unclear. This multicenter study examines the characteristics of patients with active cancer and their outcomes after PVI. METHODS: Institutional vascular quality initiative (VQI) PVI data from 3 tertiary care centers (2019-2023) were combined and expanded through a retrospective chart review to include the presence and types of cancer. All adult patients undergoing endovascular intervention for PAD, including those with claudication, chronic limb-threatening ischemia (CLTI), and acute limb ischemia (ALI), were included. The primary outcome was the composite of major amputation or mortality at 4 years in patients with cancer compared to those without. Additional long-term outcomes included reintervention, mortality, and major amputation at both 1 and 4 years. Secondary outcomes included perioperative outcomes. RESULTS: A total of 3,072 patients were included. The incidence of active cancer was 2.2% (N=68). Lung cancer was the most common, affecting 30.9% (N=21) of patients. 53% (N=36) presented with advanced stages (3/4) irrespective of cancer type. Patients with cancer were less likely to have diabetes. There was no significant difference in indication, but patients with cancer were more likely to get treated for aortoiliac disease and undergo stenting. Patients with cancer had a higher incidence of distal embolization (4.4% vs 0.6%, P=0.012) and perioperative major amputation (4.4% vs 1.3%, P=0.046). Kaplan-Meier analysis showed significantly higher mortality or amputation in patients with cancer up to 4 years (63% vs 35.1%, P<0.001). Late outcomes in patients with cancer were driven by significantly higher mortality (52.2% vs. 28.3%, p<.001) rather than adverse limb events (amputation: 14.7% vs. 11.4%, p=.50; reintervention:47.8% vs. 48.3%, p=.80). Regression analysis demonstrated independent association of cancer with the composite outcome of mortality or major amputation (aHR=2.24 [1.61-3.10]). CONCLUSION: Active cancer affects a small proportion of patients undergoing PVI but has a significant impact on perioperative limb outcomes and long-term survival. This multicenter collaboration, combining registry data and EMR review, can shed light on less common risk factors affecting lower extremity revascularization.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Caron E, Said S, Anan H, et al. Multicenter Outcomes of Peripheral Vascular Interventions in Patients with Active Cancer. J Vasc Surg. 2026. PMID: 42855020. doi:10.1016/j.jvs.2026.09.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。